The investigators are trying to learn the most effective way to treat an adolescent's eating disorder and how best to involve the parents or caregivers in this process.
Typically, parents and their child are seen together in therapy. However, this can sometimes be difficult for both the parents and the adolescent. both parents and adolescents have different concerns and are struggling with different aspects of the eating disorder. Therefore, the treatment in this study involves the parents in treatment, but does not have therapy sessions with the parents and child together.
the purpose of this study is to develop this investigational type of treatment (separated family treatment), and see what works best for adolescents and their families.
Participants meet with a therapist for 20 sessions over the course of 24 weeks. for the first 16 weeks families separate therapy sessions weekly. for the last 8 weeks families meet with the therapist bi-weekly. these bi-weekly sessions are conjoint – that is, adolescents and parents will meet with the therapist together. this is to help parents and adolescents come together as a family to continue to aid the adolescent in the treatment of his/her eating disorder.
the investigators hypothesize that adolescents who receive ASFT will demonstrate improvement in eating disorder symptoms and body-mass index, that caregivers who participate in ASFT will demonstrate decreased distress and caregiver burden, that increases in psychological acceptance will be seen for both adolescents and caregivers post-treatment, and that treatment will be viewed as both credible and acceptable to both caregiver and adolescent
Clinical Trial Conditions: Anorexia Nervosa, Subthreshold Anorexia Nervosa, Eating Disorder Not Otherwise specified, Primary Restriction
Treatments in this Clinical Trial : Acceptance and Commitment Therapy, Parent Skills Training
Clinical Trial Phase: Phase 2
Eligible Clinical Trial Participant Age : between 12 years to 18 years
Can Healthy Volunteers Participate: No
Clinical Trial Lead Sponsor: Duke University
Detailed Clinical Trial Description: the investigators are trying to learn the most effective way to treat an adolescent's eating disorder and how best to involve the parents or caregivers in this process.
Typically, parents and their child are seen together in therapy. However, this can sometimes be difficult for both the parents and the adolescent. both parents and adolescents have different concerns and are struggling with different aspects of the eating disorder. Therefore, the treatment in this study involves the parents in treatment, but does not have therapy sessions with the parents and child together.
the purpose of this study is to develop this investigational type of treatment (separated family treatment), and see what works best for adolescents and their families.
Participants meet with a therapist for 20 sessions over the course of 24 weeks. for the first 16 weeks families separate therapy sessions weekly. for the last 8 weeks families meet with the therapist bi-weekly. these bi-weekly sessions are conjoint – that is, adolescents and parents will meet with the therapist together. this is to help parents and adolescents come together as a family to continue to aid the adolescent in the treatment of his/her eating disorder.
the investigators hypothesize that adolescents who receive ASFT will demonstrate improvement in eating disorder symptoms and body-mass index, that caregivers who participate in ASFT will demonstrate decreased distress and caregiver burden, that increases in psychological acceptance will be seen for both adolescents and caregivers post-treatment, and that treatment will be viewed as both credible and acceptable to both caregiver and adolescent
The clinical trial information was obtained from clinicaltrials.gov/ct2/show/NCT01274416
- Ity Training to Improve Motor Behavior in Toddlers With or at Risk for Cerebral Palsy: A Pilot Study
- Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability in Youth (Satiety) Study
- Afatinib in HER2-treatment Failures
- Study of Treatment for Posttraumatic Stress Disorder and Substance Use
- A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic despite Treatment With H1 Antihistamines H2 Blockers and/or Leukotriene Receptor Antagonists